News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
SciClone Pharmaceuticals, Inc. Tumbles on SEC Investigation, U.S. DOJ FCPA Compliance Issues
August 10, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Street Insider -- Shares of SciClone (Nasdaq: SCLN) are taking a tumble this morning as the company reported that they have been contacted by the U.S. SEC for an investigation. Shares are down 31% to $2.40 in the morning session.
Twitter
LinkedIn
Facebook
Email
Print
Legal
MORE ON THIS TOPIC
Vaccines
ACIP Chair Questions Polio Vaccines, Values Individual Choice Over Public Benefit
January 23, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
FDA Sets Feb. 1 Launch Date for PreCheck Pilot To Strengthen Domestic Supply Chain
January 22, 2026
·
2 min read
·
Nick Paul Taylor
Vaccines
‘Almost Like a Religion’: Pfizer CEO Slams RFK Jr.’s ‘Anti-Science’ Vaccine Policies
January 22, 2026
·
2 min read
·
Tristan Manalac
Earnings
J&J Aims for $100B in Sales, Puts Stelara Patent Cliff ‘in the Rearview Mirror’
January 21, 2026
·
2 min read
·
Dan Samorodnitsky